The program is run by the agency’s Office of Orphan Products Development. The guidance explains how manufacturers should define a patient population for the device, demonstrate the device’s efficacy for that group and how demonstrating efficacy varies whether the device treats or diagnoses a disease or condition.
Related Articles on the FDA:
Commentary: Free the FDA
FDA Approves Intuitive Surgical’s Single-Site Instrumentation for Gallbladder Surgery
FDA Finds Problems in Johnson & Johnson Contract Drug Factory
